IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lifted by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 111,188 shares of the medical research company's stock after acquiring an additional 2,044 shares during the period. IQVIA makes up approximately 1.3% of Nichols & Pratt Advisers LLP MA's holdings, making the stock its 24th largest holding. Nichols & Pratt Advisers LLP MA owned about 0.06% of IQVIA worth $19,566,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. American National Bank & Trust acquired a new position in IQVIA in the 1st quarter worth $26,000. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at about $39,000. Finally, Lee Danner & Bass Inc. bought a new position in IQVIA during the 4th quarter worth approximately $44,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Barclays lowered their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Robert W. Baird reduced their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Finally, Wall Street Zen lowered IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

Shares of NYSE:IQV traded down $0.41 during trading hours on Friday, hitting $164.24. 674,106 shares of the company's stock traded hands, compared to its average volume of 1,651,146. The company's fifty day simple moving average is $150.59 and its two-hundred day simple moving average is $173.51. The company has a market cap of $28.41 billion, a price-to-earnings ratio of 22.38, a price-to-earnings-growth ratio of 1.82 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the business posted $2.54 earnings per share. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.